Saptalis Pharmaceuticals Launches Cyclosporine Ophthalmic Emulsion 0.05% and Expands Product Portfolio

HAUPPAUGE, N.Y.--(BUSINESS WIRE)--Saptalis Pharmaceuticals LLC today announced the commercial launch of Cyclosporine Ophthalmic Emulsion 0.05%, available in 30- and 60-count single-use vials, reinforcing its commitment to expanding access to high-quality treatments. Dry eye disease affects millions of patients worldwide. Cyclosporine Ophthalmic Emulsion 0.05% is a preservative-free, single-use formulation indicated to increase tear production and provides a convenient option for managing inflam